Condition (MeSH)
Cerebellar Neoplasms
ClinicalTrials.gov lists 6 trials for Cerebellar Neoplasms or a narrower condition beneath it. Aesculap AG has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Cerebellar Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Cerebellar Neoplasms trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 1 |
| 2019 | 1 |
| 2014 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cerebellar Neoplasms trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Not applicable | 1 |
| Observational | 4 |
How many Cerebellar Neoplasms trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cerebellar Neoplasms trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Aesculap AG | 1 |
Which publications cover Cerebellar Neoplasms? (130)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Melanoma antigens in pediatric medulloblastoma contribute to tumor heterogeneity and species-specificity of group 3 tumors. | Acta neuropathologica communications | 2025 | Yes |
| Evolving Biology and Therapy of WNT-Activated Medulloblastoma. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | Yes |
| Treatment of Medulloblastoma in the Adolescent and Young Adult Population: A Systematic Review. | Journal of adolescent and young adult oncology | 2025 | Yes |
| Tumour volume as a predictor of postoperative speech impairment in children undergoing resection of posterior fossa tumours: a prospective, multicentre study. | Acta neurochirurgica | 2025 | Yes |
| Preoperative 11 C-Methionine PET-MRI in Pediatric Infratentorial Tumors. | Clinical nuclear medicine | 2024 | Yes |
Showing 5 of 130 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.